Table_3.doc
Pharmacogenomics has largely been applied to the personalization of irinotecan-based treatment, focusing mainly on the study of genetic variants in adsorption, distribution, metabolism, and excretion (ADME) genes. The transcriptional control of ADME gene expression is mediated by a set of nuclear factors responding to cancer-related inflammation, which could have pharmacological implications. The aim of the present study was to uncover novel genetic predictors of neutropenia and gastrointestinal toxicity risk among 246 haplotype-tagging polymorphisms in 22 genes encoding inflammation-related cytokines and transcriptional regulators of ADME genes. The study comprised overall more than 400 metastatic colorectal cancer (mCRC) patients treated with first-line FOLFIRI, grouped in a discovery and a replication cohorts. A concordant protective effect of STAT-3 rs1053004 polymorphism against the risk of grade 3–4 gastrointestinal toxicity was observed in both the cohorts of patients (OR = 0.51, p = 0.045, q = 0.521 and OR = 0.39, p = 0.043, respectively). VDR rs11574077 polymorphism was demonstrated to affect both irinotecan biliary index (BI) and glucuronidation ratio (GR) by a pharmacokinetic analysis. This effect was consistent with an increased risk of grade 3–4 gastrointestinal toxicity in the discovery cohort (OR = 4.46, p = 0.010, q = 0.305). The association was not significant in the replication cohort (OR = 1.44, p = 0.601). These findings suggest an effect of STAT-3 and VDR polymorphisms on FOLFIRI-related gastrointestinal toxicity. If prospectively validated as predictive markers, they could be used to improve the clinical management of mCRC.
History
References
- https://doi.org//10.1111/j.1749-6632.2009.04911.x
- https://doi.org//10.1097/shk.0b013e318150762b
- https://doi.org//10.1038/clpt.2013.172
- https://doi.org//10.1517/17425255.2016.1141196
- https://doi.org//10.1200/JCO.2008.19.0314
- https://doi.org//10.1038/tpj.2015.12
- https://doi.org//10.1097/FPC.0000000000000168
- https://doi.org//10.1016/j.bcp.2012.01.030
- https://doi.org//10.1586/ecp.11.66
- https://doi.org//10.2217/pgs-2016-0095
- https://doi.org//10.1016/j.drup.2015.05.003
- https://doi.org//10.2217/pgs.13.214
- https://doi.org//10.1097/FPC.0b013e328364b6cf
- https://doi.org//10.1158/1078-0432.CCR-06-0861
- https://doi.org//10.1016/j.it.2015.06.007
- https://doi.org//10.3748/wjg.v21.i43.12234
- https://doi.org//10.2217/FON.15.138
- https://doi.org//10.1200/JCO.1997.15.4.1502
- https://doi.org//10.1038/clpt.2014.143
- https://doi.org//10.2174/156800906777441753
- https://doi.org//10.1096/fj.02-0195fje
- https://doi.org//10.1016/j.bbacli.2015.11.002
- https://doi.org//10.1038/gim.2016.33
- https://doi.org//10.3389/fphar.2017.00712
- https://doi.org//10.1016/j.tips.2015.10.006
- https://doi.org//10.3748/wjg.v20.i14.3751
- https://doi.org//10.1124/jpet.112.202242
- https://doi.org//10.1007/s00280-007-0570-0
- https://doi.org//10.3978/j.issn.2078-6891.2014.077
- https://doi.org//10.1007/s00280-007-0534-4
- https://doi.org//10.2174/187152012803833080
- https://doi.org//10.1007/s12672-013-0139-9
- https://doi.org//10.1089/jir.2014.0225
- https://doi.org//10.1002/ijc.29799
- https://doi.org//10.11131/2015/101178
- https://doi.org//10.4331/wjbc.v5.i2.231
- https://doi.org//10.1016/j.freeradbiomed.2010.09.006
- https://doi.org//10.1200/JCO.2001.19.18.3801
- https://doi.org//10.1038/clpt.2011.34
- https://doi.org//10.1200/JCO.2005.05.5400
- https://doi.org//10.1200/JCO.2009.23.6125
- https://doi.org//10.1200/JCO.2004.05.113
- https://doi.org//10.1371/journal.pone.0042401
- https://doi.org//10.1038/nrc3818
- https://doi.org//10.1371/journal.pone.0020965
- https://doi.org//10.1016/j.ejphar.2012.09.046